Paul Tudor Jones Fate Therapeutics Inc Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 48,169 shares of FATE stock, worth $79,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,169

Previous 45,290 6.36%

Holding current value

$79,960

Previous $148,000 13.51%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $8,982 - $16,036	2,879 Added 6.36%	48,169 $168,000
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $9,101 - $19,767	-2,792 Reduced 5.81%	45,290 $148,000
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $170,210 - $401,484	48,082 New	48,082 $352,000
Q3 2023 Nov 15, 2023	SELL	$2.02 - $5.04 $8,936 - $22,296	-4,424 Reduced 8.1%	50,187 $106,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $10,362 - $14,346	2,177 Added 4.15%	54,611 $259,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $1,484 - $3,891	-350 Reduced 0.66%	52,434 $299,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $57,040 - $137,856	5,785 Added 12.31%	52,784 $533,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $216,375 - $370,841	10,284 Added 28.01%	46,999 $1.05 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $384,065 - $915,666	21,601 Added 142.92%	36,715 $910,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $545,957 - $1.11 Million	-18,401 Reduced 54.9%	15,114 $586,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $1.6 Million - $2.16 Million	33,515 New	33,515 $1.96 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $239,410 - $329,371	-3,560 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $256,889 - $417,944	3,560 New	3,560 $294,000
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $1.6 Million - $4.24 Million	-42,035 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $131,523 - $175,162	4,325 Added 11.47%	42,035 $1.68 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $762,119 - $1.33 Million	37,710 New	37,710 $1.29 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $622,420 - $963,613	-46,484 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $719,107 - $1.05 Million	46,484 New	46,484 $722,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account